Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level903 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer(RAMP205) | active not recruiting | Phase 1 / Phase 2 | 40 | Verastem, Inc.INDUSTRY | 1 | Sep 2, 2025 |
| clinicaltrials |
| NCT01088789 | Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer | active not recruiting | Phase 2 | 71 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06728358 | The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract(SOCRATE) | active not recruiting | N/A | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04025840 | Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery | active not recruiting | Phase 4 | 260 | Peking University First HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03806309 | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC(TEDOPAM) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05604560 | A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer | active not recruiting | Phase 2 | 25 | Lei ZhengOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05607953 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 60 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | active not recruiting | Phase 1 / Phase 2 | 192 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02340117 | Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 28 | SynerGene Therapeutics, Inc.INDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT03073785 | Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 46 | University of NebraskaOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT06940778 | LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS(BLENTI) | active not recruiting | — | 273 | Hospital do CoracaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06938906 | Multimodal Therapy Impact on Pancreatic Cancer Survival(MMTIPS) | active not recruiting | — | 405 | National Cheng Kung UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06532331 | A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 87 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05083780 | Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer | active not recruiting | Phase 1 | 40 | Changhoon YooOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05915351 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | active not recruiting | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06920082 | Progressive Muscle Relaxation Exercises on Sleep, Fatigue and Pain in Pancreatic and Colon Cancer Patients | active not recruiting | N/A | 60 | Istanbul Sabahattin Zaim UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT02818829 | Biological and Clinical Database for Pancreatic Adenocarcinoma(BACAP) | active not recruiting | — | 1,700 | University Hospital, ToulouseOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04246203 | Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer(PROJECTION) | active not recruiting | — | 200 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06867146 | MRD in PAAD Adjuvant Therapy | active not recruiting | N/A | 60 | Peking Union Medical College HospitalOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03899636 | A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer(DIRECT) | active not recruiting | Phase 3 | 528 | Angiodynamics, Inc.INDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03899649 | A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer(DIRECT) | active not recruiting | — | 532 | Angiodynamics, Inc.INDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05880472 | Percutaneous Holmium Injection in Pancreatic Cancer(SLOTH-2a) | active not recruiting | N/A | 6 | Radboud University Medical CenterOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06815172 | PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.(PARA) | active not recruiting | — | 500 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04986930 | mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma(SABER) | active not recruiting | Phase 2 | 92 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06766019 | Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 47 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04404595 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | active not recruiting | Phase 1 / Phase 2 | 110 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer(NUMANTIA) | active not recruiting | Phase 1 / Phase 2 | 28 | Nelum CorpINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. | active not recruiting | Phase 1 | 36 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | active not recruiting | Phase 2 / Phase 3 | 140 | Oslo University HospitalOTHER | 4 | Nov 20, 2024 | clinicaltrials |
| NCT04423731 | Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) | active not recruiting | — | 251 | Oslo University HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06532344 | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer | active not recruiting | Phase 1 | 32 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT05659914 | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | active not recruiting | Phase 2 | 40 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05638698 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) | active not recruiting | Phase 2 | 24 | University of Kansas Medical CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT06429904 | Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 31 | Peking Union Medical College HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2025source: clinicaltrials